A biodegradable nanoparticle therapy induces antigen-specific regulatory immune responses in mouse models of autoimmune disease. A gliadin-containing nanoparticle treatment prevented intestinal pathology and blocked increases in inflammatory T cells in the blood after gluten challenge in celiac disease patients. Cellular and molecular mechanisms required for the therapy's antigen-specific tolerance-inducing abilities were identified. Nanoparticles are taken up by antigen-presenting cells, which leads to increased regulatory T cells and reduced inflammatory disease. The therapy aims to retrain the immune system by inhibiting effector T cells and inducing regulatory T cells as a targeted alternative to broad immunosuppression.
"We knew that if you inject these nanoparticles into an animal model, the nanoparticles get taken up by antigen presenting cells and this resulted in increased regulatory T-cells and decreased inflammatory disease. However, we did not know how this happens,"
""retrain" the immune system by inhibiting the effector T-cells promoting autoimmunity and inducing regulatory T-cells to prevent autoimmunity."
#antigen-specific-tolerance #nanoparticle-therapy #regulatory-t-cells #autoimmune-disease #celiac-disease
Read at News Center
Unable to calculate read time
Collection
[
|
...
]